Table 1 Study characteristics
Author/Year | Country | Study design | Setting | Male | Age | HF | CAD | Medication |
|---|---|---|---|---|---|---|---|---|
Du Y/2020 | Wuhan/China | Retrospective (2 centers) | Inpatient | 72.9 | 65.8a | NA | 11.8 | Anti-influenza drugs: 77.6; Lopinavir-Ritonavir: 12.9 |
Wang D/2020 | Wuhan/China | Retrospective (1 center) | Inpatient | 54.3 | 56.0 | NA | NA | Anti-influenza drugs: 89.9; Azithromycin: 18.1 |
Guo T/2020 | Wuhan/China | Retrospective (1 center) | Inpatient | 48.7 | 58.5 a | NA | 11.2 | Anti-influenza drugs: 88.8 |
Rosenberg ES/2020 | New York/USA | Retrospective (multicenter) | Inpatient | 59.7 | 63.0 | 6.7 | 12.0 | Hydroxychloroquine: 18.8; Azithromycin: 14.7; Hydroxychloroquine + Azithromycin: 51.1 |
Lei S/2020 | Wuhan/China | Retrospective (3 centers) | Inpatient | 41.2 | 55.0 | NA | NA | Lopinavir-Ritonavir: 100 |
Saleh M/2020 | New York/USA | Prospective (3 centers) | Inpatient | 57.2 | 58.5 a | 7.5 | 11.4 | Hydroxychloroquine/Chloroquine: 40.8; (Hydroxychloroquine/Chloroquine) + Azithromycin: 59.2 |
Chang D/2020 | New York/USA | Prospective (1 center) | Inpatient | 59.5 | 60.2 a | 0.9 | 5.1 | Hydroxychloroquine: 56.4; Hydroxychloroquine + Azithromycin: 43.6 |
Bhatla A/2020 | Philadelphia/USA | Retrospective (1 center) | Inpatient | 45.0 | 50.0 a | 13.0 | 11.0 | Hydroxychloroquine: 24.6; Remdesivir: 8.1 |
Chorin E/2020 | New York/USA | Retrospective (2 centers) | Inpatient | 75.0 | 64.0 a | 3.0 | 12.0 | Hydroxychloroquine: 100.0; Azithromycin: 100.0 |
Sabatino J/2020 | Catanzaro/Italy | Cross-sectional (multicenter) | Inpatient | 52.6 | 34.7 a | NA | NA | NA |
Mani VR/2020 | New York/USA | Retrospective (1 center) | Inpatient | 60.3 | 64.7 a | NA | 20.1 | Hydroxychloroquine: 21.7; Azithromycin: 12.5; Hydroxychloroquine + Azithromycin: 48.9 |
Si D/2020 | Wuhan/China | Retrospective (1 center) | Inpatient (died) | 63.6 | 64.0 | NA | 17.4 | Azithromycin: 0.8; Anti-influenza drugs: 71.9; Lopinavir- Ritonavir: 7.4; Remdesivir: 0.0 |
| Â | Â | Â | Inpatient (alive) | 32.7 | 61.5 | NA | 8.4 | Azithromycin: 2.6; Anti-influenza drugs: 83.7; Lopinavir- Ritonavir: 14.3; Remdesivir: 2.0 |
Angeli F/2020 | Varese/Italy | Retrospective (1 center) | Inpatient | 72.0 | 64 a.0 | 6.0 | 10.0 | Hydroxychloroquine: 82.0; Macrolides: 56.0; Lopinavir- Ritonavir: 54.0 |
Samuel S/2020 | New York/USA | Retrospective (1 center) | Inpatient | 57.5 | 12.6 a | NA | NA | Hydroxychloroquine: 44.0; Hydroxychloroquine + Azithromycin: 25.0; Remdesivir: 5.6; Tocilizumab: 5.6 |
Ramireddy A/2020 | Los Angeles/USA | Retrospective (1 center) | Inpatient | 61.0 | 62.3 a | 20.0 | NA | Hydroxychloroquine: 10.2; Azithromycin: 27.6; Hydroxychloroquine + Azithromycin: 62.2 |
Sala S/2020 | Milan/Italy | Cross-sectional (multicenter) | Inpatient | 66.0 | 65.0 | NA | 7.0 | Hydroxychloroquine: 100.0; Azithromycin: 100.0 |
Cao B/2020 | Beijing/China | Randomized controlled trial (1 center) | Inpatient | 60.3 | 58.0 | NA | NA | Lopinavir-Ritonavir: 49.7 |
Goyal P/2020 | New York/USA | Retrospective (2 centers) | Inpatient | 60.6 | 62.2 | NA | 13.7 | NA |
Cao J/2020 | Wuhan/China | Retrospective (1 center) | Inpatient | 52.0 | 54.0 | NA | NA | Antiviral drugs: 98.0 |
Zhang G/2020 | Wuhan/China | Retrospective (1 center) | Inpatient | 48.9 | 55.0 | NA | NA | Antiviral drugs: 88.7 |
Jun Wu/2020 | Wuhan/China | Retrospective (1 center) | Inpatient | 54.5 | 62.0 | NA | NA | Antiviral drugs: 97.0 |
Fernández-Ruiz M/2020 | Madrid/Spain | Retrospective (1 center) | Inpatient/outpatient | 77.8 | 71.0 | NA | 22.2 | Lopinavir-Ritonavir + Hydroxychloroquine: 44.4; Lopinavir-Ritonavir: 5.6; Hydroxychloroquine: 27.8 |
McCullough SA/2020 | New York/USA | Retrospective (1 center) | Inpatient | 63.2 | 64.0 | 7.3 | 14.4 | NA |
Lim JH/2020 | Daegu/Korea | Retrospective (2 centers) | Inpatient | 66.7 | 75.0 | 6.7 | NA | Hydroxychloroquine: 83.3; Lopinavir-Ritonavir: 96.7 |
Maraj I/2020 | Connecticut/USA | Retrospective (1 center) | Inpatient | 56.0 | 62.7 a | NA | 14.0 | Hydroxychloroquine: 100.0; Azithromycin: 100.0 |
Shao F/2020 | Wuhan/China | Retrospective (1 center) | Inpatient | 66.2 | 69.0 a | NA | 11.0 | NA |
Lagier JC/2020 | Marseille/France | Retrospective (multicenter) | Inpatient/outpatient | 45.6 | 45.0 a | NA | NA | Hydroxychloroquine: 2.7; Azithromycin: 3.7; Hydroxychloroquine + Azithromycin: 89.3 |
Jung HY/2020 | Daegu/Korea | Retrospective (multicenter) | Inpatient | 42.9 | 63.5 a | NA | NA | Lopinavir-Ritonavir: 100.0; Hydroxychloroquine: 50.0 |
Dubernet A/2020 | Réunion Island/France | Retrospective (1 center) | Inpatient | 69.4 | 66.0 | NA | NA | Hydroxychloroquine + Azithromycin: 63.9; Lopinavir- Ritonavir: 5.6 |
Voisin O/2020 | Paris/France | Retrospective (1 center) | Inpatient | 55.2 | 68.0 | NA | NA | Hydroxychloroquine + Azithromycin: 100.0 |
Mazzanti A/ 2020 | Pavia/Italy | Prospective (multicenter) | Inpatient | 63.0 | 69.0 | NA | NA | Hydroxychloroquin:100.0; Hydroxychloroquine + Azithromycin: 26.0; Hydroxychloroquin + Lopinavir- Ritonavir: 35.0; Hydroxychloroquine + Azithromycin + Lopinavir-Ritonavir: 6.0 |
Gupta MD/2020 | New Delhi/India | Case series (1 center) | Inpatient | 57.1 | 56.0 | 14.3 | 28.6 | NA |
Chinitz JS/2020 | New York/USA | Retrospective (1 center) | Inpatient | 42.9 | 64.0 a | NA | NA | NA |
Ferguson J/2020 | California/USA | Retrospective (2 centers) | Inpatient | 52.8 | 60.4 | 6.9 | 9.7 | Hydroxychloroquine: 22.2; Azithromycin: 45.8; Remdesivir: 44.4; Tocilizumab: 5.6 |
Argenziano MG/2020 | New York/USA | Retrospective (1 center) | Inpatient | 60.1 | 63.0 | 10.7 | 13.5 | Hydroxychloroquine: 63.9; Azithromycin: 47.6; Remdesivir: 2.1; Tocilizumab: 6.0 |
Khamis F/2020 | Muscat/Oman | Prospective (2 centers) | Inpatient | 85.0 | 48.0 a | NA | NA | Hydroxychloroquine/Chloroquine: 97.0; Azithromycin: 71.0; Lopinavir-Ritonavir: 59.0; Tocilizumab: 3.2 |
Russo V /2020 | Naples/Italy | Retrospective (multicenter) | Inpatient | 61.1 | 66.9 a | 11.1 | 15.9 | NA |
Xu H/2020 | Sichuan/China | Retrospective (1 center) | Inpatient | 49.0 | NA | NA | NA | Antiviral drugs: 100.0 |
Chen L/2020 | Guangdong/China | Retrospective (3 centers) | Inpatient | 67.0 | 59.5 a | NA | NA | Antiviral drugs: 96.0 |
Kelly M/2020 | Dublin/Ireland | Retrospective (1 center) | Inpatient | 61.9 | NA | NA | NA | Hydroxychloroquine + Azithromycin: 61.2 |
Rivinius R/2020 | Heidelberg/Germany | Retrospective (multicenter) | Inpatient | 81.0 | 58.6 a | 100.0 | NA | Hydroxychloroquine: 14.3; Azithromycin: 19.0 |
Aversa M/2020 | New York/USA | Retrospective (1 center) | Inpatient | 50.0 | 65.0 | NA | NA | Hydroxychloroquine: 84.0; Azithromycin: 75.0; Remdesivir: 9.0; Tocilizumab: 19.0 |
Wang ZH/2020 | Wuhan/China | Retrospective (1 center) | Inpatient | 64.4 | 67.4 a | NA | NA | Antiviral drugs: 88.1; Lopinavir-Ritonavir: 10.2 |
Li J/2020 | Wuhan/China | Retrospective (1 center) | Inpatient | 47.0 | 58.0 | NA | 6.0 | Antiviral drugs: 78.4 |
Rey JR/2020 | Madrid/Spain | Retrospective (1 center) | Inpatient | 54.8 | 62.3 a | 4.9 | 6.5 | Hydroxychloroquine: 77.4; Azithromycin: 45.6; Lopinavir- Ritonavir: 10.4; Tocilizumab: 7.4 |
Riker RR/2020 | Portland/USA | Retrospective (1 center) | Inpatient | 100.0 | 70.0 | 0.0 | 33.3 | Hydroxychloroquine: 66.6; Azithromycin: 100.0; Remdesivir: 33.3; Tocilizumab: 33.3 |
Beyls C/2020 | Amiens Cedex/France | Retrospective (1 center) | Inpatient | 68.3 | NA | NA | NA | Lopinavir-Ritonavir: 100 |
Sheth V/2020 | New York/USA | Retrospective (1 center) | Inpatient | 71.0 | 69.0 | NA | NA | Hydroxychloroquine: 84.0; Azithromycin: 90.0; Remdesivir: 3.2 |
Ferrando C/2020 | Barcelona/Spain | Prospective (multicenter) | Inpatient | 66.8 | 64.0 | 1.4 | NA | Hydroxychloroquine: 90.1; Azithromycin: 74.8; Lopinavir- Ritonavir: 65.2; Remdesivir: 2.9; Tocilizumab: 42.5 |
Farré N/2020 | Barcelona/Spain | Retrospective (1 center) | Inpatient | 57.1 | NA | 5.3 | NA | Hydroxychloroquine: 2.6; Azithromycin: 1.6; Hydroxychloroquine + Azithromycin: 93.3; Tocilizumab: 16.9 |
Sridhar AR/2020 | Washington/ USA | Retrospective (1 center) | Inpatient | 60.0 | 62.0 a | 16.0 | 13.0 | Hydroxychloroquine: 100.0 |
Sekhavati E/2020 | Tehran/Iran | Randomized controlled trial (1 center) | Inpatient | 50.0 | 54.3 a | NA | NA | Azithromycin: 100.0; Lopinavir-Ritonavir: 100.0 |
Satlin MJ/2020 | New York/USA | Retrospective (2 centers) | Inpatient | 63.0 | 62.0 | 9.0 | 18.0 | Hydroxychloroquine: 100.0; Azithromycin: 18.0; Remdesivir: 7.2 |
Chen L/2020 | Wuhan/China | Retrospective (1 center) | Inpatient | 76.2 | 53.0 | NA | 6.3 | Antiviral drugs: 90.5 |
Oates CP/2020 | New York/USA | Retrospective (1 center) | Inpatient | 55.0 | 69.0 | NA | 19.0 | Hydroxychloroquine: 87.0; Azithromycin: 60.0; Remdesivir: 4.0; Tocilizumab: 4.0 |
Enzmann MO/2020 | Dakota/USA | Retrospective (3 centers) | Inpatient | 56.7 | 56.0 | 10.7 | NA | Hydroxychloroquine: 6.0; Hydroxychloroquine + Azithromycin: 44.0; Lopinavir-Ritonavir: 2.0; Tocilizumab: 8.0 |